Drug Search Results
More Filters [+]

Rolipram

Alternative Names: rolipram
Latest Update: 2024-07-30
Latest Update Note: News Article

Product Description

Mechanisms of Action: PDE4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rolipram

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Sclerosis

Phase 1: Huntington Disease|Depressive Disorder|Depressive Disorder, Major|Brain Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

000824-M

P1

Terminated

Depressive Disorder

2023-02-08

06-M-0215

P1

Completed

Depressive Disorder, Major

2016-06-16

NCT01602900

P1

Completed

Huntington Disease

2012-04-12

06-M-0002

P1

Completed

Brain Diseases

2009-02-05

Recent News Events